Skip to main content
Top
Published in: Journal of General Internal Medicine 14/2022

28-01-2022 | Mood Disorders | Original Research

Prevalent Multimorbidity Combinations Among Middle-Aged and Older Adults Seen in Community Health Centers

Authors: Ana R. Quiñones, PhD, Steele H. Valenzuela, MS, Nathalie Huguet, PhD, Maria Ukhanova, MD PhD, Miguel Marino, PhD, Jennifer A. Lucas, PhD, Jean O’Malley, MPH, Teresa D. Schmidt, PhD, Robert Voss, MS, Katherine Peak, MPH, Nathaniel T. Warren, MPH, John Heintzman, MD

Published in: Journal of General Internal Medicine | Issue 14/2022

Login to get access

Abstract

Background

Multimorbidity (≥ 2 chronic diseases) is associated with greater disability and higher treatment burden, as well as difficulty coordinating self-management tasks for adults with complex multimorbidity patterns. Comparatively little work has focused on assessing multimorbidity patterns among patients seeking care in community health centers (CHCs).

Objective

To identify and characterize prevalent multimorbidity patterns in a multi-state network of CHCs over a 5-year period.

Design

A cohort study of the 2014–2019 ADVANCE multi-state CHC clinical data network. We identified the most prevalent multimorbidity combination patterns and assessed the frequency of patterns throughout a 5-year period as well as the demographic characteristics of patient panels by prevalent patterns.

Participants

The study included data from 838,642 patients aged ≥ 45 years who were seen in 337 CHCs across 22 states between 2014 and 2019.

Main measures

Prevalent multimorbidity patterns of somatic, mental health, and mental-somatic combinations of 22 chronic diseases based on the U.S. Department of Health and Human Services Multiple Chronic Conditions framework: anxiety, arthritis, asthma, autism, cancer, cardiac arrhythmia, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), congestive heart failure, coronary artery disease, dementia, depression, diabetes, hepatitis, human immunodeficiency virus (HIV), hyperlipidemia, hypertension, osteoporosis, post-traumatic stress disorder (PTSD), schizophrenia, substance use disorder, and stroke.

Key results

Multimorbidity is common among middle-aged and older patients seen in CHCs: 40% have somatic, 6% have mental health, and 24% have mental-somatic multimorbidity patterns. The most frequently occurring pattern across all years is hyperlipidemia-hypertension. The three most frequent patterns are various iterations of hyperlipidemia, hypertension, and diabetes and are consistent in rank of occurrence across all years. CKD-hyperlipidemia-hypertension and anxiety-depression are both more frequent in later study years.

Conclusions

CHCs are increasingly seeing more complex multimorbidity patterns over time; these most often involve mental health morbidity and advanced cardiometabolic-renal morbidity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430-439.CrossRef Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430-439.CrossRef
6.
go back to reference Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. Prev Chronic Dis. 2013;10(120203). Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: estimates from the National Health Interview Survey, 2010. Prev Chronic Dis. 2013;10(120203).
15.
go back to reference Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet. 2012;380(9836):37-43.CrossRef Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. The Lancet. 2012;380(9836):37-43.CrossRef
27.
go back to reference Huguet N, Larson A, Angier H, et al. Rates of undiagnosed hypertension and diagnosed hypertension without anti-hypertensive medication following the Affordable Care Act. Am J Hypertens. Published online April 30, 2021:hpab069. https://doi.org/10.1093/ajh/hpab069 Huguet N, Larson A, Angier H, et al. Rates of undiagnosed hypertension and diagnosed hypertension without anti-hypertensive medication following the Affordable Care Act. Am J Hypertens. Published online April 30, 2021:hpab069. https://​doi.​org/​10.​1093/​ajh/​hpab069
Metadata
Title
Prevalent Multimorbidity Combinations Among Middle-Aged and Older Adults Seen in Community Health Centers
Authors
Ana R. Quiñones, PhD
Steele H. Valenzuela, MS
Nathalie Huguet, PhD
Maria Ukhanova, MD PhD
Miguel Marino, PhD
Jennifer A. Lucas, PhD
Jean O’Malley, MPH
Teresa D. Schmidt, PhD
Robert Voss, MS
Katherine Peak, MPH
Nathaniel T. Warren, MPH
John Heintzman, MD
Publication date
28-01-2022
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 14/2022
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-021-07198-2

Other articles of this Issue 14/2022

Journal of General Internal Medicine 14/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine